Leader in translational research on brain diseases, and providing powerful expertise through its researchers, the ICM wants to attract foreign entrepreneurs through the French Tech Ticket.
iPEPS, the ICM’s incubator, relies on this scheme to attract new and innovative projects, in the field of biotech, medtech, and digital, to the benefit of patients with neurological disorders.
One of the missions of the Paris French Tech Ticket is to strengthen the influence of France on the international technological stage. One of the ways to achieve this goal is to improve the image of France abroad, and to attract investors and foreign entrepreneurs.
By integrating the iPEPS, the candidates benefit from high value-added services, “industrial” and financial means, allowing them to grow faster and achieve their ambition to become world leaders.
The “iPEPS-ICM” bioincubator, opened in 2012, hosts about twenty companies involved in a strong partnership with the ICM. It offers a unique environment, with more than 650 researchers and doctors present at the ICM, and thanks to the Pitié-Salpêtrière hospital, largest neurology hospital in France (more than 90 000 patients a year). iPEPS-ICM aims to accelerate the materialisation of ideas into products, by providing an ideal framework for the development of ground-breaking projects.